CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 146 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,871,914 | -17.0% | 416,759 | -4.6% | 0.00% | 0.0% |
| Q2 2023 | $5,872,851 | -22.2% | 436,968 | -4.0% | 0.00% | 0.0% |
| Q1 2023 | $7,547,862 | -36.3% | 455,239 | -28.5% | 0.00% | -50.0% |
| Q4 2022 | $11,846,000 | +48.4% | 636,741 | +2.3% | 0.00% | +33.3% |
| Q3 2022 | $7,985,000 | +446.9% | 622,355 | +198.7% | 0.00% | +200.0% |
| Q2 2022 | $1,460,000 | -10.6% | 208,321 | +5.7% | 0.00% | – |
| Q1 2022 | $1,633,000 | -55.2% | 197,080 | -63.4% | 0.00% | -100.0% |
| Q4 2021 | $3,647,000 | +1025.6% | 538,859 | +783.0% | 0.00% | – |
| Q3 2021 | $324,000 | +548.0% | 61,027 | +457.1% | 0.00% | – |
| Q1 2021 | $50,000 | +35.1% | 10,955 | 0.0% | 0.00% | – |
| Q4 2020 | $37,000 | -57.0% | 10,955 | -62.0% | 0.00% | – |
| Q3 2020 | $86,000 | -30.6% | 28,866 | +7.7% | 0.00% | – |
| Q2 2020 | $124,000 | -90.7% | 26,792 | -92.2% | 0.00% | -100.0% |
| Q4 2017 | $1,337,000 | – | 341,956 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |